Biological markers of interferon-beta therapy: Comparison among interferon-stimulated genes MxA, TRAIL and XAF-1

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 47-57

  Gilli, F ^a   Marnetto, F ^a   Caldano, M ^a   Sala, A ^a   Malucchi, S ^a   Capobianco, M ^a   Bertolotto, Antonio ^a  

^a Centro di Riferimento Regionale Sclerosi Multipla (CReSM) and Neurobiologia Clinica   (Italy)

Author keywords

Biomarkers; Interferon beta; Interferon stimulated genes; ISG; Mxa; TRAIL; XAF 1

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS 1;

ADULT; ANTIBODY DETECTION; ARTICLE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RELIABILITY; SHORT COURSE THERAPY;

ADULT; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MALE; MEMBRANE GLYCOPROTEINS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPLASM PROTEINS; REFERENCE VALUES; RNA, MESSENGER; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31644440262     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1245oa     Document Type: Article

References (46)

1. Staeheli P, Pavlovic J. Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. J Virol 1991; 65: 4498-501.
2. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001; 69: 912-20. Review.
3. von Wussow P, Jakschies D, Hochkeppel HK, Fibich C, Penner LM, Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990; 20: 2015-19.
4. Deisenhammer F, Reindel M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239-43.
5. Kracke A, von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000; 54: 193-99.
6. Vallittu AM, Halminen M, Peltoniemi J, Ilonen J, Julkunen I, Salmi A et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta 1a-treated MS patients. Neurology 2001; 58: 1786-90.
7. Pachner AR, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-β bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25.
8. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U et al. Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001; 256: 141-52.
9. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E et al. Persistent neutralizing antibodies abolish the interferon-β bioavailability in MS patients. Neurology 2003; 60: 634-39.
10. Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano, M, Di Sapio A et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neural Neurosurg Psychiatry 2004; 75: 1294-99.
11. Gilli F, Sala A, Bancone C, Salacone P, Gallo M, Gaia E et al. Evaluation of IFNα bioavailability by MxA mRNA in HCV patients. J Immunol Methods 2002; 262: 183-86.
12. Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S et al. Neutralising antibodies against IFN-β in MS: antagonisation of IFN-β mediated suppression of MMPs. Brain 2004; 127: 259-68.
13. Gilli F, Marnetto F, Caldano, M, Sala A, Malucchi S, Di Sapio A et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005; 158: 195-203.
14. Horisberger MA. Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins. J Virol 1992; 66: 4705-709.
15. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002; 3: 710-17. Review.
16. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
17. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7: 1821-31.
18. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361: 2036-43.
19. Song K, Chen V, Goke R, Wilmen A. Seidel C, Goke A et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoirnmune inflammation and cell cycle progression. J Exp Med 2000; 191: 1095-104.
20. Wendling U, Walczak H, Dorr J, Jaboci C, Weller M, Krammer PH et al. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. Cell Death Differ 2000; 7: 637-44.
21. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-49. Review.
22. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FB et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
23. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 1998; 18: 345-50.
24. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon-beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95-100.
25. WHO Expert Committee on Biological Standardisation. Thirty-fifth report. WHO Technical Report Series 725. Geneva: World Health Organization, 1985.
26. Grossberg SE, Kawade Y. The expression of potency of neutralizing antibodies for interferon and other cytokines. Biotherapy 1997; 10: 93-98.
27. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody: I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21: 729-42.
28. Kawade Y. Quantitation of neutralization of interferon by antibodies. Methods Enzymol 1986; 119: 558-73.
29. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2003; 21: 743-55.
30. Gibson UE, Held CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
31. Schumacher GA, Beebe GW, Kibler RF, Kurland LT, Kurtzke JF, McDowell F et al. Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552-68.
32. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004; 152: 126-39.
33. Kamohara H, Matsuyama W, Shimozato O, Abe K, Galligan C, Hashimoto S et al. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology 2004; 111: 186-94.
34. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OCCAR3. Cancer Res 2003; 63: 4521-26.
35. Kahl KG, Kruse N, Toyka KV, Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci 2002; 200: 53-55.
36. Ruiz de Almodovar C, Lopez-Rivas A, Ruiz-Ruiz C. Interferon-gamma and TRAIL in human breast tumor cells. Vitam Horm 2004; 67: 291-318. Review.
37. Park SY, Seol JW, Lee VJ, Cho JH, Kang HS, Kim IS et al. IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 2004; 271: 4222-28.
38. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
39. Malucchi S, Sala A, Gilli F, Bottero, R, Di Sapio A, Capobianco M et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031-37.
40. Perini P, Calabrese M, Blasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing- remitting MS. J Neurol 2004; 251: 305-309.
41. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing- remitting multiple sclerosis. Mult Scler 2004; 10: 126-38.
42. Matusevicius D, Kivisakk P, Navikas VV, Tian W, Soderstrom M, Fredrikson S et al. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur J Neurol 1998; 5: 265-75.
43. Rudick AR. Biological impact of interferon antibodies and complexities in assessing their clinical significance. Neurology 2003; 61: 531-34. Review.
44. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36.
45. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon-β-1b. Neurology 2003; 60: 37-43.
46. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419-29.